The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Vera Therapeutics Inc shares valued at $296,032 were sold by Fordyce Marshall on Feb 21 ’25. At $27.89 per share, Fordyce Marshall sold 10,613 shares. The insider’s holdings dropped to 213,740 shares worth approximately $4.56 million following the completion of this transaction.
Also, Fordyce Marshall sold 9,075 shares, netting a total of over 250,882 in proceeds. Following the sale of shares at $27.65 each, the insider now holds 204,665 shares.
Before that, MARSHALL FORDYCE had added 9,075 shares to its account. In a trade valued at $245,932, the Director bought Vera Therapeutics Inc shares for $27.10 each.
Analysts at Wolfe Research started covering the stock with ‘”an Outperform”‘ outlook in a report released in early February. As of January 28, 2025, Goldman has initiated its “Buy” rating for VERA. Earlier on November 21, 2024, Wells Fargo initiated its rating. Their recommendation was “an Overweight” for VERA stock.
Analyzing VERA Stock Performance
During the last five days, there has been a drop of approximately -3.18%. Over the course of the year, Vera Therapeutics Inc shares have dropped approximately -49.56%. Shares of the company reached a 52-week high of $43.76 on 01/06/25 and a 52-week low of $18.53 on 04/09/25. A 50-day SMA is recorded $24.11, while a 200-day SMA reached $35.93.
Support And Resistance Levels for Vera Therapeutics Inc (VERA)
According to the 24-hour chart, there is a support level at 21.06, which, if violated, would cause prices to drop to 20.79. In the upper region, resistance lies at 21.54. The next price resistance is at 21.75. RSI (Relative Strength Index) is 41.79 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at -1.51, which suggests the price will decrease in the coming days. Percent R is at 89.47%, indicating bearish price movement. Stochastics %K at buying indicates that the stock is to be held.
